All Episodes
Displaying 121 - 127 of 127 in total
22-48 Dr. Robert Ang, President & CEO, Vor Biopharma
Vor Biopharma has a unique approach to a particular kind of cancer – Acute Myeloid Leukemia – perhaps better known to you, as AML. Dr. Robert Ang is Vor's President & ...
22-47 Dr. James Mackay, President & CEO, Aristea Therapeutics
Too much of a good thing spells trouble - in this case, that would be neutrophils – the white blood cells that act as our immune system’s first line of defense. It's c...
22-46 Dr. Maria Maccecchini, Founder, President & CEO, Annovis Bio
Alzheimer’s, Parkinson’s and ALS, among others, are often grouped as Neurodegenerative Disorders. While they each present a different profile of symptoms, what do they...
22-16 Triple-Negative Breast Cancer is the most aggressive of all
Anixa is pioneering a new approach to preventing the truly aggressive triple-negative form of breast cancer. Based on research from Cleveland Clinic, this approach has...
Dr. George Yancopoulos, CEO, Regeneron
Dr. George Yancopoulosis is the President and Chief Scientific Officer of Regeneron. Regeneron is successful on many levels but is perhaps best known for its Covid tre...
Dr. Daniel Bloomfield, Chief Medical Officer, Anthos Therapeutics
Blood clots of any sort are dangerous. So dangerous in fact, that 1 in 4 people die from blood clots - independent of medical condition, medicines they take, or medica...
Mark Litton, President & CEO, Athira Pharma
Alzheimer’s, Parkinson’s dementia, and other neurodegenerative diseases continue to be challenging, but now new science has led to a better understanding of the natura...